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Abstract
Management of Clostridium difficile infections is usually accomplished through appropriate antimicrobial
therapy. However, in patients that do not respond to this therapy, rapid and potentially lethal progressive organ
dysfunction care occurs. Although supportive care and continued antimicrobial therapy is important, surgical
therapy is critical to eradication of the inflammatory process and reversal of the dysregulated immunity
associated with severe C. difficile infections. In the following paper, the role of colectomy is reviewed.
S ixty years after the first report of Staphylococcusenterocolitis, we are in the midst of a Clostridium diffi-
cile infection (CDI) resurgence [1] and its accompanying
morbidity and mortality rates [2]. Our knowledge of this
pathogen has evolved considerably over the last half century.
Clostridium difficile is a spore-forming, anaerobic, gram-
positive bacterium. This microbe is responsible for gastro-
intestinal infections that range in severity from mild colitis to
toxic megacolon and death. Clostridium difficile remains the
leading cause of healthcare-associated diarrhea and now ri-
vals methicillin-resistant Staphylococcus aureus (MRSA) as
the most common organism to cause healthcare-associated
infection in the United States [3,4]. In addition, infections
caused by C. difficile have been reported in patients previ-
ously believed to be at ‘‘low risk,’’ lacking the typical risk
factors for infection, such as prior antimicrobial therapy or
extended stay in a healthcare facility [2,4]. Accompanying
the increase in prevalence is an associated increase in disease
severity [5], no longer allowing CDI to be brushed aside as an
indolent infection. Many recent cases of CDI have resulted in
substantial morbidity and mortality rates, causing healthcare
providers to search for a more integrated and streamlined
management scheme to more optimally transition from
medical management to surgical intervention [6].
The newfound CDI prevalence and disease severity appear
to be multi-factorial, but can only be partially explained by
recent advances in CDI pathophysiology. The primary viru-
lence factors of C. difficile are Toxin A (TcdA) and Toxin B
(TcdB). These toxins are potent cytotoxic enzymes that
damage the human colonic mucosa, causing the traditional
symptoms of CDI. A binary toxin called cytolethal distending
toxin (CDT) has been identified in approximately 6% of C.
difficile isolates and is a characteristic feature of a hypervir-
ulent C. difficile strain. This toxin is hypothesized to poten-
tiate the toxicity of TcdA and TcdB, leading to more severe
disease [7]. The emergence of a novel, hypervirulent strain of
C. difficile has now been reported across the United States,
Canada, and Europe [5,7,8]. This strain of C. difficile has
been characterized as toxinotype III, North American pulsed-
field gel electrophoresis (PFGE) type 1, and polymerase
chain reaction (PCR)-ribotype 027 (NAP1/027). This new
strain appears to produce greater amounts of Toxins A and B
and has a deletion in the tcdC gene, which potentially down
regulates toxin production. In addition, this hypervirulent
strain exhibits increased sporulation in comparison to non-
virulent strains of C. difficile, which may contribute to the
widespread observed disease severity [7].
Although the number of CDI cases is increasing, the sur-
gical intervention rate appears to be constant, causing many
healthcare providers concern. According to the Nationwide
Inpatient Sample of the Healthcare Cost and Utilization
Project (HCUP), the total number of patients assigned the
International Classification of Diseases, Ninth Revision
(ICD-9) code for CDI (008.45) in acute care facilities has
increased from 138,954 in 2000 to nearly 350,000 in 2008,
whereas the number of surgical interventions has remained
constant [9,10]. The most well-known risk factors for the
development of CDI are the administration of antibiotics,
inappropriate use of broad-spectrum agents, and lack of ap-
propriate streamlining based on culture/susceptibility data.
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Almost every antibiotic has been implicated in the develop-
ment of CDI, but the most commonly cited agents include
clindamycin, cephalosporins, and fluoroquinolones. Ad-
vanced age is also associated with increased risk for CDI, as
is a prolonged stay in a healthcare facility such as an acute
care institution or a long-term care facility. In addition, high
severity of illness is also a notable risk factor for CDI
[6,9,11–14].
Other factors have been linked to CDI with varying levels
of supporting evidence. Patients with inflammatory bowel
disease are at greater risk than the general population for
acquiring CDI [12]. This association may be because of the
multiple courses of antibiotics necessary for frequent disease
flares in addition to the use of immunosuppressive agents to
maintain disease remission. Gastrointestinal surgery has also
been linked to CDI, although this factor is not a confirmed
risk factor for disease. There also has been a considerable
amount of interest in proton pump inhibitors (PPIs) and re-
sulting gastric acid suppression as a causative factor of CDI
[11]. Proton pump inhibitors have been implicated in the de-
velopment of community-acquired CDI, although conflicting
data exist to date. A high severity of illness and immunosup-
pression has also been attributed to increased risk of CDI in
some cases [14]. Certain factors can also put patients at risk for
CDI recurrence and even poorer outcomes. These factors in-
clude advanced age >65 y; administration of antibiotics after
initial treatment of CDI; prolonged hospitalization or stay in a
long-term care facility; a defective immune response to Toxin
A; and gastric acid suppression [13,15–17].
Confirmation of CDI can be challenging considering the
multitude of diagnostic tests available and their individual
and collective lack of specificity and sensitivity for predicting
clinically substantial infection. Enzyme immunoassay (EIA),
tissue culture cytotoxicity, glutamate dehydrogenase (GDH),
polymerase chain reaction (PCR), and stool culture for
C. difficile are all efficacious. There are clearly benefits to any
of these diagnostic modalities depending on the clinical sit-
uation [6].
The basic principles of CDI therapy include discontinuing
the offending antimicrobial agent, sending a stool specimen
early for C. difficile testing, initiating CDI therapy empirically
or following confirmation of diagnosis, and monitoring for
symptom resolution or progression with awareness of potential
for recurrence after treatment discontinuation. Therapy may
include pharmacotherapy with agents such as vancomycin (the
only U.S. Food and Drug Administration [FDA]-approved
treatment for CDI) or metronidazole, or supportive care [6].
According to the Society for Healthcare Epidemiology of
America (SHEA)/Infectious Diseases Society of America
(IDSA) guidelines, mild to moderate disease is defined as
white blood cell count (WBC) <1500 cells/mcL or serum
creatinine (SCr) concentration <1.5 times the pre-morbid
concentration. In these patients, the recommended therapy is
metronidazole 500mg three times per day per oral for 10–14 d.
Alternately, severe disease is defined asWBC ‡1500 cells/
mcL or SCr concentration ‡1.5 times the pre-morbid con-
centration. The recommended treatment for severe CDI is
vancomycin 125mg four times per day PO for 10–14 d. Se-
vere, complicated disease is defined as hypotension or shock,
ileus, or toxic megacolon. These patients should receive
vancomycin 500mg four times per day PO or by nasogastric
tube plus metronidazole 500mg IV every 8 h. It is important
to note that the vancomycin dose in this setting is based on
original, empiric studies; it is not clear that 500mg is nec-
essary [6]. Lastly, a surgical consult should be obtained in all
patients with complicated CDI and operative intervention
considered in all patients with hypotension requiring vaso-
pressor therapy, clinical signs of sepsis and organ dysfunc-
tion, mental status changes, WBC >50,000 cells/ml, lactate
‡5 mmol/L, or failure to improve on medical therapy for 5 d
[6]. Once severe, complicated CDI is recognized and evalu-
ated for potential surgical intervention, it should be note that
colectomy may be lifesaving, but is associated with increased
risk of death if WBC is >50,000 cells/mcL and lactate is
>5mg/dL. Indications of severe, complicated disease course
include the following: Elevated and rising WBC, elevated
SCr concentration, elevated serum lactate, clinical and ra-
diographic evidence of severe ileus, and impending toxic
megacolon. Vancomycin per rectum should also be consid-
ered if ileus is severe or operative approaches are not suit-
able [6,18].
Surgical options for severe CDI intervention include seg-
mental partial colon resection, subtotal colectomy with end
ileostomy (TCEI), and diverting loop ileostomy with colonic
irrigation [19], each approach having its benefits and disad-
vantages. Outcome following colectomy with ileostomy
versus partial colectomy for severe CDI is difficult to inter-
rupt based on limited data. Most authors favor TCEI over
partial colectomy alone [19]. Following colectomy for severe
CDI in one study, patients with virulent fulminant CDI ex-
perienced a reduced mortality rate from 58% to 34% [20].
Some of the factors associated with improved mortality rates
following colectomy for severe CDI include age >75 y, ab-
sence of immune suppression, shock requiring vasopressor
amines, WBC between 19,900 and 49,900 cells/mcL, and
peak lactate 2.2 mmol/L to 4.9 mmol/L [20]. Conversely,
proposed factors associated with colectomy failure include
delayed surgical intervention occurring too late in the course
of the disease, incorrect patient selection because of a lack of
clearly defined guidelines, and lastly, the clinical course of
the disease is difficult to predict. In order to minimize co-
lectomy failure in patients with severe CDI, many providers
advocate early surgical intervention, which is associated with
an increased rate of operative intervention and survival [21].
However, early TCEI in CDI is far from life-saving with a
recent meta-analysis revealing a 30 d mortality rate of 41.3%
[22]. This stark reality has led some investigators to employ
earlier operative intervention in an attempt to mitigate the
severe CDI-associated mortality rates. One small series in-
corporated early diverting loop ileostomy with vancomycin
colonic lavage and found a 30% reduction in post-operative
mortality rates compared with historical TCEI control patients
[23]. Although these results sound promising, a more recent
meta-analysis found that when TCEI was not performed, re-
operation to resect further bowel was necessary in 16% of
patients [22]. The authors conclude that TCEI should be the
primary surgical treatment for patients with severe CDI. This
notion goes hand in hand with the premise that less extensive
surgery may have a role in selected patients with earlier-stage
CDI; however, the supporting data are sparse at best [24].
Given the importance of rapid source control via TCEI for
fulminant CDI, it is important to understand that continued
management of any remaining infected colonic tissue must
occur. In order to do this, current recommendations suggest
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the use of oral and rectal vancomycin to eradicate any po-
tential continued source of infection [25,26].
Conclusion
Severe CDI should have early surgical consult. Indications
for surgical intervention remain poorly defined. Subtotal
colectomy with end ileostomy appears superior to partial
colectomy and other surgical approaches in regards to the
need for subsequent re-operation. Although loop ileostomy
with colonic washout is promising, data remain limited and
ability to define full extent of necrosis may be limited.
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